Rhombencephalosynapsis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:59315Q04.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Rhombencephalosynapsis (RES) is a rare brain malformation that affects the cerebellum — the part of the brain at the back of the head that controls balance, coordination, and movement. In this condition, the two halves of the cerebellum (called hemispheres) are fused together instead of being separate, and a structure called the vermis is partially or completely missing. The name comes from 'rhombencephalon,' the medical term for the back part of the brain. There are no widely used synonyms, though it is sometimes abbreviated as RES. This condition is usually present from birth and is most often discovered through brain imaging such as an MRI. The severity varies widely from person to person. Some individuals have mild symptoms, while others face significant challenges with movement, balance, learning, and development. Many children with RES also have problems with eye movement control, and some have additional brain or body abnormalities. There is currently no cure for rhombencephalosynapsis. Treatment focuses on managing symptoms and supporting development. This may include physical therapy, occupational therapy, speech therapy, and medications to control seizures if they occur. Early intervention and ongoing support can make a meaningful difference in quality of life for those living with this condition.

Key symptoms:

Poor balance and coordinationDelayed motor milestones such as sitting, standing, or walkingIntellectual disability or learning difficultiesAbnormal eye movements (such as eyes moving together in an unusual way)Muscle stiffness or unusual muscle toneSeizuresSpeech and language delaysDifficulty with fine motor tasks like writing or buttoning clothesHydrocephalus (fluid buildup in the brain) in some casesBehavioral challenges

Clinical phenotype terms (30)— hover any for plain English
Esophageal atresiaHP:0002032Agenesis of cerebellar vermisHP:0002335
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Rhombencephalosynapsis.

View clinical trials →

No actively recruiting trials found for Rhombencephalosynapsis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Rhombencephalosynapsis community →

No specialists are currently listed for Rhombencephalosynapsis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Rhombencephalosynapsis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open RhombencephalosynapsisForum →

No community posts yet. Be the first to share your experience with Rhombencephalosynapsis.

Start the conversation →

Latest news about Rhombencephalosynapsis

No recent news articles for Rhombencephalosynapsis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my child's rhombencephalosynapsis, and what does that mean for their development?,Should we pursue genetic testing, and could this condition be inherited or recur in future pregnancies?,What therapies do you recommend, and how often should my child receive them?,Is my child at risk for hydrocephalus, and how will we monitor for it?,What signs should prompt me to seek emergency care?,Are there any clinical trials or research studies we could participate in?,What educational and community support resources are available for our family?

Common questions about Rhombencephalosynapsis

What is Rhombencephalosynapsis?

Rhombencephalosynapsis (RES) is a rare brain malformation that affects the cerebellum — the part of the brain at the back of the head that controls balance, coordination, and movement. In this condition, the two halves of the cerebellum (called hemispheres) are fused together instead of being separate, and a structure called the vermis is partially or completely missing. The name comes from 'rhombencephalon,' the medical term for the back part of the brain. There are no widely used synonyms, though it is sometimes abbreviated as RES. This condition is usually present from birth and is most of

How is Rhombencephalosynapsis inherited?

Rhombencephalosynapsis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Rhombencephalosynapsis typically begin?

Typical onset of Rhombencephalosynapsis is neonatal. Age of onset can vary across affected individuals.